Why All the Fuss About Oxidative Phosphorylation (OXPHOS)?

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2020 Oct 26

PMID 33103432

Citations 46

Authors

Yibin Xu

Ding Xue

Armand Bankhead 3rd

Nouri Neamati

Affiliations

Soon will be listed here.

Abstract

Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications.

Citing Articles

Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile.

Burban A, Tessier C, Larroquette M, Guyon J, Lubiato C, Pinglaut M EMBO Mol Med. 2025; 17(3):469-503.

PMID: 39901019 PMC: 11903783. DOI: 10.1038/s44321-025-00195-6.

Pan-cancer analysis of Arp2/3 complex subunits: focusing on ARPC1A's role and validating the ARPC1A/c-Myc axis in non-small cell lung cancer.

Zhou C, Chen Y, Chen S, Hu L, Wang J, Wang Y Front Immunol. 2025; 15:1491910.

PMID: 39867911 PMC: 11759278. DOI: 10.3389/fimmu.2024.1491910.

DNA replication stress underpins the vulnerability to oxidative phosphorylation inhibition in colorectal cancer.

Zhao X, Han M, Yan Q, Yue Y, Ye K, Zhang Y Cell Death Dis. 2025; 16(1):16.

PMID: 39809754 PMC: 11733219. DOI: 10.1038/s41419-025-07334-4.

Single-cell dissection of multifocal bladder cancer reveals malignant and immune cells variation between primary and recurrent tumor lesions.

Liu S, Feng C, Tan L, Zhang D, Li Y, Han Y Commun Biol. 2024; 7(1):1659.

PMID: 39702554 PMC: 11659313. DOI: 10.1038/s42003-024-07343-7.

Collective total synthesis of chartreusin derivatives and bioactivity investigations.

Yi H, Liang S, Li J, Liu H, Liao J, Liu D Chem Sci. 2024; 16(3):1241-1249.

PMID: 39677934 PMC: 11635980. DOI: 10.1039/d4sc05629a.

References

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

Parey K, Brandt U, Xie H, Mills D, Siegmund K, Vonck J . Cryo-EM structure of respiratory complex I at work. Elife. 2018; 7. PMC: 6168287. DOI: 10.7554/eLife.39213. View

Alvarez-Calderon F, Gregory M, Pham-Danis C, DeRyckere D, Stevens B, Zaberezhnyy V . Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2014; 21(6):1360-72. PMC: 4359967. DOI: 10.1158/1078-0432.CCR-14-2146. View

Aleo M, Luo Y, Swiss R, Bonin P, Potter D, Will Y . Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014; 60(3):1015-22. DOI: 10.1002/hep.27206. View

Glick G, Rossignol R, Lyssiotis C, Wahl D, Lesch C, Sanchez B . Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther. 2014; 351(2):298-307. PMC: 4201277. DOI: 10.1124/jpet.114.218099. View

Bajpai R, Sharma A, Achreja A, Edgar C, Wei C, Siddiqa A . Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020; 11(1):1228. PMC: 7060223. DOI: 10.1038/s41467-020-15051-z. View

Zickermann V, Wirth C, Nasiri H, Siegmund K, Schwalbe H, Hunte C . Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. Science. 2015; 347(6217):44-9. DOI: 10.1126/science.1259859. View

Yan Y, Wang Y, Tan Q, Lubet R, You M . Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia. 2005; 7(12):1053-7. PMC: 1501176. DOI: 10.1593/neo.05532. View

10.

Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M . Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006; 13(5):587-92. DOI: 10.1111/j.1442-2042.2006.01342.x. View

11.

Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K . Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Res. 2016; 76(13):3904-15. PMC: 4930686. DOI: 10.1158/0008-5472.CAN-15-2534. View

12.

Salomon A, Voehringer D, Herzenberg L, Khosla C . Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol. 2001; 8(1):71-80. DOI: 10.1016/s1074-5521(00)00057-0. View

13.

Zhang X, Fryknas M, Hernlund E, Fayad W, De Milito A, Olofsson M . Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014; 5:3295. PMC: 3929804. DOI: 10.1038/ncomms4295. View

14.

Guo L, Shestov A, Worth A, Nath K, Nelson D, Leeper D . Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine. J Biol Chem. 2015; 291(1):42-57. PMC: 4697178. DOI: 10.1074/jbc.M115.697516. View

15.

Zacksenhaus E, Shrestha M, Liu J, Vorobieva I, Chung P, Ju Y . Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis. Trends Cancer. 2017; 3(11):768-779. DOI: 10.1016/j.trecan.2017.09.002. View

16.

Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C . Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc. 2012; 7(6):1235-46. DOI: 10.1038/nprot.2012.058. View

17.

Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E . Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia. 2013; 27(11):2129-38. PMC: 10869165. DOI: 10.1038/leu.2013.107. View

18.

Aldakkak M, Stowe D, Chen Q, Lesnefsky E, Camara A . Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release. Cardiovasc Res. 2007; 77(2):406-15. DOI: 10.1016/j.cardiores.2007.08.008. View

19.

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

20.

Lam T, Jeong Y, Kim S, Ahn S . New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways. Cancer Sci. 2017; 109(3):699-709. PMC: 5834796. DOI: 10.1111/cas.13482. View